PCM
CTNM

Prelude Capital Management’s Contineum Therapeutics CTNM Stock Holding History

Prelude Capital Management’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-13,920
Closed -$55.3K – 1426
2025
Q2 		$55.3K Buy
+13,920
New +$60.5K 0.01% 958

Other funds holding CTNM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Prelude Capital Management's CTNM Position: Q3 2025 in Review

Prelude Capital Management sold out of Contineum Therapeutics (CTNM) in Q3 2025, closing a stake of 13,920 shares — an estimated $55.3K sold.

Prelude Capital Management first reported a position in CTNM in Q2 2025 and held it in 1 quarter. The position peaked at $55.3K in Q2 2025. 62 funds tracked by Wall St. Rank hold CTNM as of Q3 2025.

  • Prelude Capital Management reported no remaining Contineum Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Prelude Capital Management sold 13,920 Contineum Therapeutics shares in Q3 2025, an estimated $55.3K.
  • Prelude Capital Management first reported a position in Contineum Therapeutics in Q2 2025 and held it in 1 quarter.
  • Prelude Capital Management's Contineum Therapeutics position peaked at $55.3K in Q2 2025.
  • 62 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q3 2025.

Based on Prelude Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.